PHAT – phathom pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Phathom Pharmaceuticals (NASDAQ:PHAT) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Phathom Pharmaceuticals (NASDAQ:PHAT) was given a new $16.00 price target on by analysts at Barclays PLC.
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
Form 4 Phathom Pharmaceuticals, For: Dec 19 Filed by: Parikh Asit
Form 4 Phathom Pharmaceuticals, For: Dec 18 Filed by: Breedlove Robert Charles
Form 4 Phathom Pharmaceuticals, For: Dec 17 Filed by: Cook Anne Marie
Form 4 Phathom Pharmaceuticals, For: Dec 17 Filed by: Basta Steven L
Form 4 Phathom Pharmaceuticals, For: Nov 28 Filed by: Basta Steven L
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.